Impact of COVID-19 restrictions liberalization on air quality: a case study of Chongqing, Southwest China.

Publication date: Oct 28, 2024

To mitigate the societal impact of the COVID-19 pandemic, China implemented long-term restrictive measures. The sudden liberalization at the end of 2022 disrupted residents’ daily routines, making it scientifically intriguing to explore its effect on air quality. Taking Chongqing City in Southwest China as an example, we examined the impact of restriction liberalization on air quality, identified potential sources of pollutants, simulated the effects of abrupt anthropogenic control relaxation using a Random Forest Model, and applied an optimized model to predict the post-liberalization pollutant concentrations. The results showed increases in PM (72. 3%), PM (67. 7%), and NO (21. 9%) concentrations, while O concentration decreased by 20. 5%. Although potential pollution source areas contracted, pollution levels intensified with northeastern Sichuan, interior Chongqing, and northern Guizhou being major contributors to pollutant emissions. Anthropogenic emissions accounted for 26. 7 ~ 33% changes in PM and PM concentrations while meteorological conditions contributed to 40. 2 ~ 43. 3% variations observed during the period. The optimized model demonstrated a correlation between predicted and observed values with R ranging from 0. 70 to 0. 89, enabling accurate prediction of post-liberalization pollutant concentrations. This study can enhance our understanding regarding the impact of sudden social lockdown relaxation events on air quality while providing support for urban air pollution prevention.

Concepts Keywords
China Air Pollutants
Daily Air Pollutants
Forest Air Pollution
Liberalization Air quality
Pandemic China
Chongqing city
Cities
COVID-19
COVID-19 restrictions liberalization
Environmental Monitoring
Humans
Meteorological normalization
Ozone
Ozone
Particulate Matter
Particulate Matter
Random forest
SARS-CoV-2

Semantics

Type Source Name
disease MESH COVID-19
drug DRUGBANK Medical air
disease IDO quality
drug DRUGBANK Ozone

Original Article

(Visited 1 times, 1 visits today)